Sunshine Biopharma warrant holders approve amendment reducing exercise price to $0.11

Sunshine Biopharma Inc.

Warrant holders approved amendment to reduce Tradeable Warrants exercise price to $0.11.
736,242 warrants voted in favor (76.4% of 963,693 outstanding), 62,429 against, 3,930 abstentions.
Amendment also eliminates restriction on CEO Steve Slilaty's voting rights under Series B Preferred Stock.
Special meeting of warrant holders held on October 12, 2023.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Sunshine Biopharma Inc. shareholders approved Amend the Warrant Agent Agreement to reduce the exercise price of Tradeable Warrants to $0.11 and eliminate the provision prohibiting the CEO from exercising voting rights under his Series B Preferred Stock at the 2023-10-12 meeting.

Outcome: passed
Meeting: 2023-10-12

Exact text from the filing

Holders of 736,242 Tradeable Warrants voted in favor of the amendment (representing 76.4% of 963,693 outstanding Tradeable Warrants), votes against were 62,429, and there were 3,930 abstentions.

View on SEC.gov

Browse all shareholder votes →

Sunshine Biopharma Inc. filing history →

Source: SEC EDGAR

accession 0001683168-23-007129

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.